Nova Scotia Health COVID-19 Non-severe Therapy Consult Service: Lessons from a Hospital Pharmacy-Based Model.
作者信息
Ramsey Tasha D, d'Entremont-Harris Mackenzie, Nodwell Lisa, Goodall Barbara, Barrett Lisa
机构信息
BScPharm, ACPR, PharmD, is the Clinical Therapeutics and Prophylactics Lead: Emerging and Re-Emerging Infections, Pharmacy Department, Queen Elizabeth II Health Sciences Centre, Nova Scotia Health, and Assistant Professor, College of Pharmacy, Faculty of Health, Dalhousie University, Halifax, Nova Scotia.
BSc, BScPharm, ACPR, is a Clinical Pharmacist (Research), Pharmacy Department, Queen Elizabeth II Health Sciences Centre, Nova Scotia Health, Halifax, Nova Scotia.
出版信息
Can J Hosp Pharm. 2024 Aug 14;77(3):e3578. doi: 10.4212/cjhp.3578. eCollection 2024.
Abstract
摘要
相似文献
1
Nova Scotia Health COVID-19 Non-severe Therapy Consult Service: Lessons from a Hospital Pharmacy-Based Model.新斯科舍省卫生厅新冠病毒非重症治疗咨询服务：基于医院药房模式的经验教训
Can J Hosp Pharm. 2024 Aug 14;77(3):e3578. doi: 10.4212/cjhp.3578. eCollection 2024.
2
The geographic accessibility of pharmacies in Nova Scotia.新斯科舍省药店的地理可达性。
Can Pharm J (Ott). 2013 Jan;146(1):39-46. doi: 10.1177/1715163512473062.
3
Adoption of the Nova Scotia (Canada) Community Pharmacy Medication Management Program, 1-Year Post-Initiation.加拿大新斯科舍省社区药房药物管理项目实施一年后采用情况。
J Popul Ther Clin Pharmacol. 2017 Feb 1;24(1):e46-e55. doi: 10.22374/17106222.24.1.6.
4
This Nova Scotia pharmacy was founded by a knight.这家新斯科舍省的药店是由一位骑士创办的。
Mod Pharm. 1948 Mar;33(2):12.
5
Fare well to Nova Scotia? Public health investments remain chronically underfunded.告别新斯科舍省？公共卫生投资仍然长期资金不足。
Can J Public Health. 2021 Apr;112(2):186-190. doi: 10.17269/s41997-021-00478-8. Epub 2021 Feb 24.
6
Facilitating oral COVID-19 therapy utilization through a pharmacy consult service.通过药房咨询服务促进口服 COVID-19 治疗药物的使用。
J Am Pharm Assoc (2003). 2023 Jul-Aug;63(4):1237-1241. doi: 10.1016/j.japh.2023.04.010. Epub 2023 Apr 20.
7
Home care: the cornerstone of health renewal in Nova Scotia.居家护理：新斯科舍省健康恢复的基石。
Leadersh Health Serv. 1995 Nov-Dec;4(6):5-7, 14.
8
Comparison of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 (COX-2) inhibitors use in Australia and Nova Scotia (Canada).比较澳大利亚和新斯科舍省（加拿大）非甾体抗炎药和环氧化酶-2（COX-2）抑制剂的使用情况。
Br J Clin Pharmacol. 2009 Jul;68(1):106-15. doi: 10.1111/j.1365-2125.2009.03410.x.
9
Maternal and perinatal outcomes of eclampsia: Nova Scotia, 1981-2000.子痫的孕产妇及围产期结局：新斯科舍省，1981 - 2000年
J Obstet Gynaecol Can. 2004 Feb;26(2):119-23. doi: 10.1016/s1701-2163(16)30487-x.
10
Suicide and drug toxicity mortality in the first year of the COVID-19 pandemic: use of medical examiner data for public health in Nova Scotia.新冠大流行第一年的自杀和药物毒性死亡率：利用新斯科舍省法医数据进行公共卫生研究。
Health Promot Chronic Dis Prev Can. 2022 Feb 16;42(2):60-67. doi: 10.24095/hpcdp.42.2.02. Epub 2021 Nov 10.
引用本文的文献
1
Nova Scotia Health Influenza Treatment Team: Virtual Care Pathway to Antiviral Treatment.新斯科舍省卫生流感治疗团队：抗病毒治疗的虚拟护理途径。
Can J Hosp Pharm. 2025 Aug 13;78(3):e3760. doi: 10.4212/cjhp.3760. eCollection 2025.
本文引用的文献
1
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.奈玛特韦片/利托那韦片组合包装口服药用于伴有进展为重症高风险因素的 COVID-19 门诊患者。
N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16.
2
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.瑞德西韦早期治疗可降低门诊患者重症 COVID-19 进展风险
N Engl J Med. 2022 Jan 27;386(4):305-315. doi: 10.1056/NEJMoa2116846. Epub 2021 Dec 22.
Zotero 插件